Bleeding prophylaxis with the investigational factor VIIIa mimetic bispecific antibody Mim8 (denecimig) was superior to ...
Today, the New England Journal of Medicine (NEJM) published 26-week results from the phase 3 FRONTIER2 trial evaluating the ...
Expression Therapeutics, Inc., a clinical-stage biopharmaceutical company developing a curative autologous stem cell therapy for hemophilia A, today announced that the U.S. Food and Drug ...
The special day shines a light on a rare yet serious blood disorder. Experts stress that while the condition cannot be ...
A rare condition that's been around since the 1950s now has a modern treatment creating a promising future for those who've ...
SAN DIEGO -- The investigational monoclonal antibody marstacimab reduced the rate of treated bleeds in patients with hemophilia A or B without inhibitors to factor VIII or factor IX, the phase III ...
World Hemophilia Day spotlights the rare blood disorder that prevents the blood from clotting and can be dangerous when left ...
Hemophilia is a rare genetic bleeding disorder affecting clotting ability. Here are its symptoms, treatment options, and ...
Hemophilia A is a genetic disorder that affects how well your blood clots. With treatment and proactive management, many people with hemophilia A can lead typical, active lives. Hemophilia is a broad ...
Up to a few decades ago a considerable proportion of patients with hemophilia died prematurely because of hemophilia. Tragically, many deaths were the result of childhood injury or surgery. Over the ...
Hemophilia is a bleeding disorder that requires careful daily management. Experts highlight five key things to avoid, ...
The Health Mentors Program pairs health sciences students with individuals living with chronic blood disorders, fostering learning through stories and conversation.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results